Caring for patients with functional hypothalamic amenorrhea?

Consider the KYRIAD study

The KYRIAD clinical study is currently underway to investigate potential treatment options for women affected by functional hypothalamic amenorrhea (FHA). FHA can result from weight loss, psychological stress, or high levels of physical activity, with each contributing differently to a patient’s clinical presentation and health risks. Treatment intervention is essential to help address concerns related to menstrual health, fertility, bone density, and mental wellbeing. As the principal investigator, I would like to invite you to consider KYRIAD as an opportunity for your patients with FHA to access emerging treatments.

KYRIAD is a phase 2, randomized, double-blind, placebo-controlled clinical research study for women with FHA. This study aims to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of an investigational treatment.

Over the course of the study, the study treatment or placebo will be administered as a subcutaneous injection.

Patients are expected to participate in this study for approximately 11 months. During the study, participants will have approximately 18 study visits.

Qualified participants may be reimbursed for travel to and from study visits. Medical care related to their participation, including the study treatment, may be provided at no cost.

How Can You Help?

KYRIAD is enrolling approximately 34 people with FHA nationwide. The success of KYRIAD depends on physicians referring potential study participants. Your patients may be eligible if they are:

Please note: Other protocol-defined inclusion/exclusion criteria apply.  

The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria.

Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.

If you have potentially eligible and interested patients, empower them with options and discuss the KYRIAD study. You may also contact the nearest study site to refer them.

Please note that this clinical trial will use investigational drug products, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities, and which has not received marketing authorization in any country.

Find a study site near you!

Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with FHA.